Drug Trial Radar · NCT06897579
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
40
Actual
Start
Apr 7, 2025
Primary completion
Apr 15, 2026
Study completion Apr 15, 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus carboplatin/cisplatin + etoposide + Tislelizumab sequential Tislelizumab in the first-line treatment of extensive stage small cell lung cancer.
Conditions
- Extensive Stage Small Cell Lung Cancer
Interventions
Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsuleDrug
Carboplatin for injection inhibits DNA synthesis, thereby preventing cancer cell division and reproduction/Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Bemosubebezumab injection is a humanized recombinant anti-Programmed cell death ligand 1 (PD-L1) monoclonal antibody/Anlotinib hydrochloride capsule is a tyrosine kinase inhibitor.
Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injectionDrug
Carboplatin for injection inhibits DNA synthesis and thus prevents the division and reproduction of cancer cells/Cisplatin for injection binds to DNA and interferes with the DNA replication and transcription process, thereby inhibiting the proliferation of tumor cells/etoposide injection interferes with the division process of cancer cells to inhibit their growth and spread/Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: From enrollment until the first onset of disease progression or death from any cause, evaluation is expected to take 2 years
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Maanshan People's Hospital
Maanshan, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Peking University People´s Hospital
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Medical University 2nd Affiliated Hospital
Quanzhou, Fujian, China
The Second Hospitai. & Clinicae Medical School . Lanzhou University
Lanzhou, Gansu, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangzhou, China
The fourth hospital of hebei medical university
Shijiazhuang, Hebei, China
Tangshan People's Hospital
Tangshan, Hebei, China
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The Second People's Hosital of Jiaozuo
Jiaozuo, Henan, China
Henan Provincial People'S Hospital
Zhengzhou, Henan, China
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, Henan, China
Jingzhou Central Hospital
Jingzhou, Hubei, China
Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Baotou Cancer Hospital
Baotou, Inner Mongolia, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Shenyang Tenth People's Hospital
Shenyang, Liaoning, China
The First Affiliated Hospital of Shandong First Medical University
Jinnan, Shandong, China
Linyi City People's Hospital
Linyi, Shandong, China
The Second Affiliated Hospital Of Xi'an Jiaotong University
Xi'an, Shannxi, China
Shanxi Cancer hospital
Taiyuan, Shanxi, China
Sichuan cancer hospital
Chengdu, Sichuan, China
Dongyang Municipal People's Hospital
Dongyang, Zhejiang, China
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China
Ningbo No.2 Hospital
Ningbo, Zhejiang, China
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.